Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humansROBERTSON, Stella M; CURTIS, Michael A; SCHLECH, Barry A et al.Survey of ophthalmology. 2005, Vol 50, pp S32-S45, issn 0039-6257, SUP1Article

A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissuesOWEN, Geoffrey R; BROOKS, Amy C; JAMES, Olushola et al.Journal of ocular pharmacology and therapeutics. 2007, Vol 23, Num 4, pp 335-342, issn 1080-7683, 8 p.Article

Safety and tolerability of olopatadine 0.2% in children and adolescentsLICHTENSTEIN, Steven J; PASQUINE, Terry A; EDWARDS, Michael R et al.Journal of ocular pharmacology and therapeutics. 2007, Vol 23, Num 4, pp 366-371, issn 1080-7683, 6 p.Article

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: A randomized, double-masked environmental studyABELSON, Mark B; GOMES, Paul J; VOGELSON, Cullen T et al.Clinical therapeutics. 2004, Vol 26, Num 8, pp 1237-1248, issn 0149-2918, 12 p.Article

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertensionSCHUMAN, Joel S; KATZ, Gregory J; LEWIS, Richard A et al.American journal of ophthalmology. 2005, Vol 140, Num 2, pp 242-250, issn 0002-9394, 9 p.Article

Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertensionNETLAND, Peter A; ROBERTSON, Stella M; KENNETH SULLIVAN, E et al.Advances in therapy. 2003, Vol 20, Num 3, pp 149-163, issn 0741-238X, 15 p.Article